ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,767.68
1.40%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Soligenix Inc (SNGX)

  7. Soligenix Inc (SNGX) Noticias

SNGX Soligenix Inc

0.418
0.0135 (3.34%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Soligenix Inc SNGX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.0135 3.34% 0.418 18:59:38
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.402 0.3958 0.4297 0.4045 0.4045
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202406:30PRNUSSoligenix Extends Patent Protection for its Filovirus..
18/4/202407:30PRNUSSoligenix Announces Pricing of $4.75 Million Public Offering
15/4/202406:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
11/4/202406:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
03/4/202406:30PRNUSSoligenix Announces Agreement on the Design of a Second..
15/3/202406:30PRNUSSoligenix Announces Recent Accomplishments and Year End 2023..
08/2/202406:30PRNUSSoligenix Announces Formation of Behçet's Disease Medical..
25/1/202406:30PRNUSSoligenix to Present at The Microcap Conference
08/1/202406:30PRNUSFDA Grants Soligenix "Fast Track" Designation for Dusquetide..
04/1/202406:30PRNUSSoligenix Announces Top-line Results of the Phase 2a Study..
02/1/202406:30PRNUSSoligenix Announces Publication Demonstrating Complete..
22/12/202315:05EDGAR2Form 8-K - Current report
17/12/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
15/12/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202315:03EDGAR2Form 8-K - Current report
08/12/202316:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202316:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202316:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202316:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202315:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
01/12/202306:30PRNUS"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
30/11/202306:30PRNUSSoligenix Receives FDA IND Clearance for Phase 2 Clinical..
17/11/202315:05EDGAR2Form 8-K - Current report
17/11/202315:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
13/11/202315:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202306:30PRNUSSoligenix Announces Recent Accomplishments And Third Quarter..
20/10/202315:05EDGAR2Form 8-K - Current report
20/10/202315:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
17/10/202312:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
17/10/202312:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/10/202315:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/10/202306:30PRNUSSoligenix to Present at The ThinkEquity Conference
13/10/202312:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
25/9/202306:30PRNUSSoligenix Announces Achievement of Two-Year Stability with..
22/9/202315:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/9/202315:05EDGAR2Form 8-K - Current report
22/9/202315:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
15/9/202315:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
15/9/202315:05EDGAR2Form 8-K - Current report
30/8/202315:05EDGAR2Form S-3 - Registration statement under Securities Act of..
21/8/202316:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21/8/202306:30PRNUSSoligenix Announces Recent Accomplishments And Second..
14/8/202315:09EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
10/8/202306:30PRNUSHyBryte™ Expanded Treatment Trial in Cutaneous T-Cell..
07/8/202315:07EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
07/8/202315:05EDGAR2Form DEF 14A - Other definitive proxy statements
11/7/202306:30PRNUSSoligenix Announces Expansion of SGX302 (Synthetic..

Su Consulta Reciente

NASDAQ
SNGX
Soligenix
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados